ABclonal Technology Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#9568

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • ABclonal Technology's estimated annual revenue is currently $17.1M per year.(i)
  • ABclonal Technology's estimated revenue per employee is $155,000
  • ABclonal Technology's total funding is $282.1M.

Employee Data

  • ABclonal Technology has 110 Employees.(i)
  • ABclonal Technology grew their employee count by 25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes. ABclonal has a comprehensive prokaryotic and eukaryotic protein expression system, advanced mouse monoclonal antibody production system and a fourth-generation rabbit monoclonal antibody technology. Our advanced technology allows the development of in vitro diagnostic products and customized IVD materials used in the early research and development of raw materials development services. Our clients span across the globe, including internationally renowned corporations, such as Novartis, Genetek, BGI Genomics, Novogene, 3DMed, and Maxim. #Biotechnology #LifeScience #Antibody #ResearchTools

keywords:N/A

$282.1M

Total Funding

110

Number of Employees

$17.1M

Revenue (est)

25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ABclonal Technology News

2021-02-22 - ABclonal Biotechnology Closes $93M Series C

ABclonal Biotechnology, a Woburn, Mass.-based global life science tools and services provider, completed its $92.9m Series C financing. The round was led by Sequoia Capital China and LYFE Capital, with participation from Sigma Square Capital, Kinghall Ventures, and Lucion Capital. Led by Zack ...

2021-02-22 - ABclonal Biotechnology Raises $93 Million Series C

ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital. Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and ...

2021-02-22 - ABclonal Biotechnology Closes $93M Series C Financing

ABclonal Biotechnology, a Woburn, Mass.-based global life science tools and services provider, completed its $92.9m Series C financing. The round was led by Sequoia Capital China and LYFE Capital, with participation from Sigma Square Capital, Kinghall Ventures, and Lucion Capital. Led by Zack ...

02/25/2019 - ABclonal Technology Partners with BenchSci to Boost ...

BOSTON, Feb. 25, 2019 (GLOBE NEWSWIRE) -- ABclonal Technology, a new and growing provider of biology research reagents and services, ...

09/13/2018 - ABclonal Technology Unveils Next-Generation Sequencing ...

BOSTON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ABclonal Technology, a dynamic and growing provider of biological reagents for life science ...

08/28/2019 - Viperin catalyzes methionine oxidation to promote protein ...

Therefore, BAC technology provides a powerful tool to probe the function and ..... The anti-GST mouse antibody was purchased from ABclonal.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.6M112-5%N/A
#2
$32.8M1133%N/A
#3
$28.7M1172%N/A
#4
$37.9M118N/AN/A
#5
$39.3M119-6%N/A